Interestingly, also CXCR4 inhibition results effective in reverting tolerogenic polarization of tumor microenvironment (42) and in restoring sensitivity to CTLA-4 and PD-1 checkpoints inhibitors (24, 43). The gene discussed is CXCR4; the disease is neoplasm.